GT Biopharma Inc. (GTBP)
NASDAQ: GTBP
· Real-Time Price · USD
2.40
-0.05 (-2.04%)
At close: May 02, 2025, 3:59 PM
2.33
-2.71%
After-hours: May 02, 2025, 04:19 PM EDT
-2.04% (1D)
| Bid | 2.26 |
| Market Cap | 6.07M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -13.16M |
| EPS (ttm) | -7.29 |
| PE Ratio (ttm) | -0.33 |
| Forward PE | -1.42 |
| Analyst | Buy |
| Ask | 2.6 |
| Volume | 8,939 |
| Avg. Volume (20D) | 464,664 |
| Open | 2.52 |
| Previous Close | 2.45 |
| Day's Range | 2.38 - 2.52 |
| 52-Week Range | 1.72 - 10.66 |
| Beta | 1.31 |
About GTBP
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed ...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 27, 2018
Employees 1
Stock Exchange NASDAQ
Ticker Symbol GTBP
Website https://www.gtbiopharma.com
Analyst Forecast
According to 1 analyst ratings, the average rating for GTBP stock is "Buy." The 12-month stock price forecast is $11, which is an increase of 359.29% from the latest price.
Stock Forecasts2 months ago
+21.18%
GT Biopharma shares are trading higher after the c...
Unlock content with
Pro Subscription
4 months ago
+60.57%
GT Biopharma shares are trading higher. Roth MKM initiated coverage on the stock with a Buy rating and set its price target at $11.
